Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Subscribe To Our Newsletter & Stay Updated
